



Attorney Docket No. P63796US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Franz ENZMANN et al.

Serial No.: 10/783,029 P63796US1

Filed: February 23, 2004

For: TRANSDERMAL ORAL AND INTRAVENOUS FORMULATIONS OF 2,3-DIMETHOXY-5-METHYL-6-DECAPRENYL-1,4-BENZOQUINONE

TERMINAL DISCLAIMER

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


MSE Pharmazeutika GmbH, a corporation of Germany, the exclusive owner of the entire right, title, and interest in the subject patent application, by virtue of an assignment recorded at Reel/Frame 010361/00496-7, hereby disclaims the terminal part of any patent granted on the above identified application that would extend beyond the expiration date of the full statutory term as defined in 35 USC §§ 154-156 and 173 of U.S. Pat. No. 6,228,891 ("the prior patent") not shortened by terminal disclaimer, and hereby agrees that any patent granted on the above identified application shall be enforceable only for and during such period that such patent is commonly owned with the prior patent, which agreement is to be binding upon the grantee, its successor or assigns; but, does not disclaim any terminal part of any patent granted on the subject patent application prior to the expiration date of the full statutory term of the prior patent if it expires for failure to pay a maintenance fee, is held unenforceable or is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole, has all claims canceled by reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term.

The requisite fee of \$55.00 is submitted herewith.

JACOBSON HOLMAN PLLC
400 Seventh Street, N.W.
The Jenifer Building
Washington, D.C. 20004
Tel.: (202) 638-6666
Date: July 14, 2004

Respectfully submitted,

By:


William E. Player
Reg. No. 31,409